In this newly created position, Brandon will lead manufacturing and operations at the company's 183,000 square foot Department of Defense Advanced Development and Manufacturing facility in Alachua, Florida.
Prior to joining Ology Bioservices, Brega served in various positions at Merck and Co., most recently as Associate vice president, Plant Management at the company's Durham, North Carolina location the largest vaccines-only facility in Merck's network.
Prior to joining Merck, Brega worked for a number of animal health manufacturers including Pfizer Inc., Wyeth Pharmaceuticals, Boehringer Ingelheim and Merial Ltd., leading operations and technical organizations in the production of vaccines, biologics and sterile injectables.
He has broad base of experience with both drug substance and drug product manufacturing across both small and large molecules.
Brega holds both a Bachelor of Science in Biology and Master of Arts in Management from Doane University and earned a Masters Certification in Six Sigma and Lean Six Sigma Black Belt from Villanova University.
Ology Bioservices serves both government and commercial clients, specialising in biologic drug substance manufacturing, from early stage through commercial product.
The company has 183,000 square feet of manufacturing, process development and QA/QC space in its Department of Defense Advanced Development and Manufacturing Facility in Florida.
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio